Table 1.
Peptide-Based Vaccination Trials
| Phase | Indication | CTAs | Year of Publication |
|---|---|---|---|
| I | Prostate cancer | NY-ESO-1 | 2014 |
| I | Advanced malignancies | NY-ESO-1 | 2007 |
| I | Neuroblastoma and sarcoma | MAGE-A1, MAGE-A3, NY-ESO-1 | 2015 |
| II | Metastatic melanoma | MAGE-A3, GP100, Tyrosinase, MAGE-A2, MAGEA1 | 2012 |
| III | NSCLC | MAGE-A3 | 2009 |
| III | Melanoma skin cancer | MAGE-A3 | 2010 |
| II | Gastric cancer | DEPDC1, URLC10, FoxM1, Kif20A, VEGFR1 | 2017 |
| I/II | Urothelial carcinoma of the bladder | DEPDC1, MPHOSPH1 | 2016 |
| I/II | Esophageal squamous cell carcinoma | TTK, LY6K, IMP3 | 2009/2012 |
| I | Gastric cancer | LY6K | 2014 |
| I | Gastric cancer | URLC10, VEGFR1 | 2014 |
| I | NSCLC | CDCA1, LY6K, VEGFR1, VEGFR2 | 2013 |
| I | Pancreatic cancer | CDCA1, Kif20A, VEGFR1, VEGFR2 | 2013 |
| II | HNSCC | CDCA1, LY6K, IMP3 | 2015 |
| I | ESCC | TTK, URLC10, KOC1, VEGFR1, VEGFR2 | 2014 |
| I | Advanced solid cancer | KOC1, TTK, URLC10, DEPDC1, MPHOSPH1 | 2016 |